Thyroid Dysfunction Diagnosis and Treatment

Introduction to Thyroid Dysfunction

• Elevated TSH levels are typically associated with hypothyroidism, whereas low TSH levels are associated with hyperthyroidism, and symptoms such as palpitations, chest tightness, and anxiety are more characteristic of hyperthyroidism, according to the American College of Endocrinology 1
• Thyroid dysfunction and anxiety disorders frequently coexist, with significant comorbidity between anxiety and thyroid disorders, as reported by the American Psychiatric Association 1

Comorbid Conditions and Thyroid Dysfunction

• Fluctuating thyroid function in conditions like thyroiditis can cause transient hyperthyroid symptoms followed by hypothyroid symptoms, as noted by the Endocrine Society 2
• Hashimoto's thyroiditis is the most common autoimmune thyroid disorder and the leading cause of hypothyroidism in industrialized nations, characterized by chronic autoimmune destruction of the thyroid gland that often leads to progressive thyroid dysfunction, according to the American Academy of Family Physicians 3
• Patients with Hashimoto's thyroiditis may present with symptoms such as fatigue, muscle cramps, constipation, cold intolerance, hair loss, voice changes, weight gain, intellectual slowness, and insomnia, as reported by the American Family Physician 3
• Strong HLA associations, particularly with HLA-DR/DQ genes, can be either predisposing or protective, according to the American Diabetes Association 4
• Patients with Hashimoto's thyroiditis may also have other autoimmune disorders, such as Addison's disease, vitiligo, celiac sprue, autoimmune hepatitis, myasthenia gravis, and pernicious anemia, as reported by the American Diabetes Association 4
• Excessive iodine consumption may trigger autoimmune thyroiditis in genetically susceptible individuals, as suggested by the American Association for the Study of Liver Diseases 5
• Hashimoto's thyroiditis is frequently associated with other autoimmune conditions, including autoimmune thyroid diseases (10-23% of HT patients), systemic lupus erythematosus (2.8-3% of HT patients), Sjögren syndrome (2.8-7% of HT patients), rheumatoid arthritis (2-4% of HT patients), and inflammatory bowel disease (2-11.4% of HT patients), according to the Clinical and Molecular Hepatology guidelines 6

Diagnosis of Thyroid Dysfunction

• Thyroid stimulating hormone (TSH) is the most sensitive initial screening test for thyroid dysfunction, and Free Thyroxine (Free T4) is used to distinguish between subclinical and overt hypothyroidism, according to 7, 8
• The initial laboratory evaluation for patients with depressive symptoms should include TSH, Free T4, and thyroid antibodies (TPO-Ab and TG-Ab) to screen for hypothyroidism, as recommended by the Endocrine Society 1
• The American Thyroid Association recommends measuring Free T3 (FT3) in symptomatic patients with minimal FT4 elevations 9
• TPO antibodies and TSH receptor antibodies (TRAb) are used as diagnostic markers for Graves' disease, with TRAb being the primary marker, and should be tested alongside TSH, Free T4, and Free T3 as initial thyroid function tests 10
• The presence of Thyroglobulin Antibodies (TG-Ab) is associated with symptom burden in Hashimoto's patients, including fragile hair, face edema, edema of the eyes, and harsh voice 9

Treatment of Thyroid Dysfunction

• The standard treatment for hypothyroidism resulting from Hashimoto's thyroiditis is levothyroxine (LT4) oral T4 monotherapy at doses ranging from 1.4 to 1.8 mcg/kg/day based on the degree of preserved thyroid functionality and lean body mass, as recommended by the Annals of Internal Medicine 7
• For patients with confirmed hypothyroidism and depressive symptoms, primary treatment with levothyroxine (LT4) at 1.4-1.8 mcg/kg/day based on thyroid functionality and lean body mass is recommended, according to the American Thyroid Association 1
• For patients with subclinical hypothyroidism and depression, consideration of levothyroxine treatment, especially with TPO antibody positivity, is suggested by the European Thyroid Association 1
• For patients with depression and normal thyroid function, standard antidepressant therapy and consideration of thyroid function monitoring during treatment are recommended by the National Institute of Mental Health 1
• For patients on levothyroxine, monitoring TSH and Free T4 every 6-12 months once stable, and assessing for improvement in both hypothyroid and depressive symptoms, is recommended by the Endocrine Society 1
• The American Medical Association recommends monitoring every 2-4 weeks until stable during treatment initiation, and every 3-6 months once stable 8
• The American College of Obstetricians and Gynecologists recommends more frequent monitoring (every 2-4 weeks) in pregnant women with Hashimoto's thyroiditis, and evaluating TSH and FT4 in women who develop a goiter during pregnancy or after delivery 3
• Attributing all symptoms to depression without screening for thyroid dysfunction, inadequate thyroid replacement, overlooking subclinical hypothyroidism, ignoring thyroid antibodies, and failing to consider T3 augmentation are common pitfalls in managing patients with overlapping hypothyroidism and depression, as noted by the American College of Physicians 1
• TPO antibody status may influence treatment outcomes, with TPO antibody-positive patients potentially developing hypothyroidism more frequently after radioactive iodine therapy 10
• The presence of TPO antibodies may be associated with reduced relapse rate after radioactive iodine therapy, although evidence is still evolving 10
• For treatment-resistant cases, consideration of combination T4/T3 therapy in patients with persistent depressive symptoms despite normalized TSH, and T3 augmentation has shown benefit in approximately 25% of treatment-resistant depression cases, as noted by the American Psychiatric Association 1